Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus toripalimab with or without local therapy in locoregional recurrent renal cell carcinoma (phase II)
ChiCTR2600125307Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of axitinib and toripalimab in renal cell carcinoma (RCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year progression-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
axitinibtoripalimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2600125307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125307.